Shares of IsoRay Inc. (AMEX: ISR), a developer, manufacturer and seller of isotope-based medical products and devices for the treatment of cancer and other malignant diseases, have risen sharply in trading today.
At last check, ISR shares were trading 20.73% higher at $1.34 on above average volume of 2.56 million. The stock touched an intra-day high of $1.38 in trading today.
ISR this week announced another step forward in international adoption of its GliaSiteÂ® radiation therapy system. GliaSite is the worldâ€™s only liquid radiation balloon catheter device used in treatment of brain cancers.
ISR this week announced that it shipped its first orders to Germany. Meanwhile, the company continues to receive inquiries for the device.
Dwight Babcock, CEO of IsoRay, said that the medical community is clearly becoming aware of the innovative alternative that GliaSite presents as an important advance over previous brain cancer treatments.